Evaluation of the effect of cyclophosphamide in the treatment of refractory nephrotic syndrome
环磷酰胺治疗难治性肾病综合征的效果评价

摘要

目的 剖析将环磷酰胺用于难治性肾病综合征群体中，于其确切效能与安全维度所产生的具体价值。方法 截取2024年5月至2025年7月区间内赴本院就医的80例难治性肾病综合征病例，循随机数字表法等分作对照组、观察组（各40例）。对照组予以他克莫司实施免疫抑制治疗，观察组则辅以环磷酰胺展开联合阻击。结果 观察组斩获的临床总有效率达85.00%，远逾对照组的60.00%（P<0.05）；观察组药物不良反应总罹患率17.50%，较对照组40.00%呈显著收敛（P<0.05）。结论 引入环磷酰胺介入难治性肾病综合征的临床施治，能有效提高疾病缓解价值的根本上，将副反应风险发生率控于较低区间，颇具临床拓用价值。

Abstract

Objective To analyze the specific value of cyclophosphamide in the treatment of refractory nephrotic syndrome in terms of its efficacy and safety.
Methods A total of 80 cases of refractory nephrotic syndrome treated in our hospital from May 2024 to July 2025 were selected and randomly divided into a control group and an observation group (40 cases each) using the random number table method. The control group was treated with tacrolimus for immunosuppression, while the observation group was treated with cyclophosphamide in combination.
Results The total clinical effective rate of the observation group was 85.00%, significantly higher than that of the control group (60.00%) (P < 0.05); the total incidence of adverse drug reactions in the observation group was 17.50%, significantly lower than that in the control group (40.00%) (P < 0.05).
Conclusion   The introduction of cyclophosphamide in the clinical treatment of refractory nephrotic syndrome can effectively improve the disease remission rate and keep the incidence of adverse reactions at a low level, which has significant clinical application value.